SCHEMBL4940152

SCHEMBL4940152

COc1ccccc1CNC(=O)CCCc1nnc(SCc2cccc(Cl)c2)n1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.53
TP53 P04637 2/20 0.52
ALDH1A1 P00352 8/20 0.50
NPSR1 Q6W5P4 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 2/20 0.44
GLA P06280 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4944620 0.98 TP53 (0.52) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4945459 0.98 TP53 (0.53) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4944071 0.95 TP53 (0.52) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4945331 0.95 ALDH1A1 (0.54) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4944445 0.94 HPGD (0.51) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4941208 0.91 HPGD (0.56) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4945531 0.91 TP53 (0.51) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4947311 0.91 TP53 (0.47) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4946883 0.90 TP53 (0.48) HPGDTP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4946305 0.90 TP53 (0.52) HPGDTP53ALDH1A1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US claimed
EP-1458381-B1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS (AN) 2005-11-30 EP claimed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US claimed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
EP-1458381-B1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS (AN) 2005-11-30 EP disclosed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187275-A1 Triazoles as oxytocin antagonists OXTR, AVPR2, AVPR1B HPGD 561/4885TP53 4351/4885ALDH1A1 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.